Receive our newsletter – data, insights and analysis delivered to you
  1. Deals Analysis
March 18, 2019updated 19 Mar 2019 2:34pm

Pharma industry M&A deals in February 2019 total $28.83bn globally

Total pharma industry M&A deals in February 2019 worth $28.83bn were announced globally, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the code below into your website to display the chart.

The value marked a decrease of 68.7% over the previous month and a drop of 39% when compared with the last 12-month average, which stood at $20.74bn.

Comparing deals value in different regions of the globe, North America held the top position, with total announced deals in the period worth $27.72bn. At the country level, the US topped the list in terms of deal value at $26.41bn.

In terms of volumes, North America emerged as the top region for pharma industry M&A deals globally, followed by Asia-Pacific and then Europe.

The top country in terms of M&A deals activity in February 2019 was the US with 14 deals, followed by China with four and Switzerland with two.

In 2019, as of the end of February 2019, pharma M&A deals worth $120.91bn were announced globally, marking an increase of 196.8% year on year.

Pharma industry M&A deals in February 2019: Top deals

The top five pharma industry M&A deals accounted for 96.5% of the overall value during February 2019.

The combined value of the top five pharma industry M&A deals stood at $27.81bn, against the overall value of $28.83bn recorded for the month. The top announced pharma industry M&A deal tracked by GlobalData in February 2019 was Danaher’s $21.4bn asset transaction with General Electric.

In second place was the $4.3bn acquisition of Spark Therapeutics by F. Hoffmann-La Roche and in third place was Ipsen’s $1.3bn acquisition of Clementia Pharmaceuticals.

The $510m acquisition of CiToxLAB Group by Charles River Laboratories International and Merck Sharp & Dohme’s acquisition of Immune Design for $300m held fourth and fifth positions, respectively.

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.

 

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU